International Journal of Hematology

, Volume 109, Issue 3, pp 299–308 | Cite as

Decline of forced expiratory volume in 1 s after allogeneic hematopoietic cell transplantation is a good indicator for pulmonary damage and is associated with busulfan use

  • Ken SagouEmail author
  • Shun Ukai
  • Yoshitaka Adachi
  • Nobuaki Fukushima
  • Kazutaka Ozeki
  • Akio Kohno
Original Article


Reduced pulmonary function is commonly observed after allogeneic hematopoietic stem cell transplantation (HSCT); however, its relationship with the development of noninfectious pulmonary complications (NIPCs) is unclear, and the impact of changes in pulmonary function test (PFT) values on HSCT outcome remains controversial. We conducted a retrospective study including 150 patients to investigate changes in PFTs and impact on clinical outcome. PFT data at around 1 year after HSCT were available in 84 patients, and showed a significant time-dependent decline in percentage predicted forced expiratory volume in 1 s and other parameters. We focused on %FEV1, calculated decline of %FEV1 from pretransplant to around 1 year after HSCT (Δ%FEV1), and divided patients into good-Δ%FEV1 or poor-Δ%FEV1 groups, using a cut-off point of 20% decline of Δ%FEV1. In the poor-Δ%FEV1 group, half of the patients developed NIPCs. In the good-Δ%FEV1 group, PFT values were maintained, whereas those of the poor-Δ%FEV1 group declined significantly. Multivariate analysis showed that busulfan use was a risk factor for %FEV1 decline, and poor-Δ%FEV1 was a risk factor for overall survival. These data indicate that decline of %FEV1 may be a useful indicator of pulmonary damage after HSCT, and is strongly associated with busulfan use.


Pulmonary function test (PFT) Percentage predicted forced expiratory volume in 1 s (%FEV1) Pulmonary damage Busulfan Hematopoietic stem cell transplantation (HSCT) 



We acknowledge all the physicians, nurses, and staff who contributed to the patient care at the Department of Hematology and Oncology in Konan Kosei Hospital.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12185_2018_2581_MOESM1_ESM.docx (810 kb)
Supplementary material 1 (DOCX 809 KB)


  1. 1.
    Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:749–59.CrossRefPubMedGoogle Scholar
  2. 2.
    Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, et al. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:1702–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Oh AL, Patel P, Sweiss K, Chowdhery R, Dudek S. DR. Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2016;51:283–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Sørensen PG, Ernst P, Panduro J, Møller J. Reduced lung function in leukaemia patients undergoing bone marrow transplantation. Scand J Haematol. 1984;32:253–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Link H, Reinhard U, Blaurock M, Ostendorf P. Lung function changes after allogenic bone marrow transplantation. Thorax. 1986;41:508–12.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sutedja TG, Apperley JF, Hughes JM, Aber VR, Kennedy HG, Nunn P, et al. Pulmonary function after bone marrow transplantation for chronic myeloid leukaemia. Thorax. 1988;43:163–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rodríguez-Roisin R, Roca J, Grañena A, Agustí AG, Marín P, Rozman C. Lung function in allogeneic bone marrow transplantation recipients. Eur Respir J. 1989;2:359–65.PubMedGoogle Scholar
  8. 8.
    Badier M, Guillot C, Delpierre S, Vanuxem P, Blaise D, Maraninchi D. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant. 1993;12:457–61.PubMedGoogle Scholar
  9. 9.
    Tran BT, Halperin A, Chien JW. Cigarette smoking and outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1004–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ringdén O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindeløv L, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Blood. 1999;93:2196–202.PubMedGoogle Scholar
  11. 11.
    Bruno B, Souillet G, Bertrand Y, Werck-Gallois MC, So Satta A, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant. 2004;34:143–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Singh AK, Karimpour SE, Savani BN, Guion P, Hope AJ, Mansueti JR, et al. Pretransplant pulmonary function tests predict risk of mortality following fractionated total body irradiation and allogeneic peripheral blood stem cell transplant. Int J Radiat Oncol. 2006;66:520–7.CrossRefGoogle Scholar
  13. 13.
    Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1261–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL, et al. Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer. 2001;92:1949–58.CrossRefPubMedGoogle Scholar
  15. 15.
    Tait RC, Burnett AK, Robertson AG, McNee S, Riyami BM, Carter R, et al. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease. Int J Radiat Oncol Biol Phys. 1991;20:1219–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Lund MB, Kongerud J, Brinch L, Evensen SA, Boe J. Decreased lung function in one year survivors of allogeneic bone marrow transplantation conditioned with high-dose busulphan and cyclophosphamide. Eur Respir J. 1995;8:1269–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Schwarer AP, Hughes JM, Trotman-Dickenson B, Krausz T, Goldman JM. A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation. Transplantation. 1992;54:1002–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, et al. Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. Biol Blood Marrow Transplant. 2015;21:1127–31.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Thompson PA, Lim A, Panek-Hudson Y, Tacey M, Hijazi R, Ng AP, et al. Screening with spirometry is a useful predictor of later development of noninfectious pulmonary syndromes in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:781–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208–14.CrossRefPubMedGoogle Scholar
  21. 21.
    Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, et al. Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:337–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplant. 2013;48:1253–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.Google Scholar
  24. 24.
    Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMedGoogle Scholar
  26. 26.
    Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30–45.CrossRefPubMedGoogle Scholar
  27. 27.
    Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.CrossRefPubMedGoogle Scholar
  28. 28.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, et al. Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Int J Hematol. 2018;107:578–85.CrossRefPubMedGoogle Scholar
  30. 30.
    Norman BC, Jacobsohn DA, Williams KM, Au B, Au MA, Lee SJ, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients. Bone Marrow Transplant. 2010;46:1369–73.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chien JW, Martin PJ, Flowers ME, Nichols WG, Clark JG. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;33:759–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Hear Lung Transplant. 2002;21:297–310.CrossRefGoogle Scholar
  33. 33.
    Vergnon JM, Boucheron S, Riffat J, Guy C, Blanc P, Emonot A. Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases. La Rev Med interne. 1988;9:377–83.CrossRefGoogle Scholar
  34. 34.
    Cooper JA, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–40.PubMedGoogle Scholar
  35. 35.
    Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol. 2006;33:98–105.CrossRefPubMedGoogle Scholar
  36. 36.
    Hartman A-R, Williams S, Dillon J. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22:439–43.CrossRefPubMedGoogle Scholar
  37. 37.
    Ljungman P, Hassan M, BéKássy A, Ringdén O, Öberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1997;20:909–13.CrossRefPubMedGoogle Scholar
  38. 38.
    Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transpl. 2001;27:1121–4.CrossRefGoogle Scholar
  39. 39.
    Kashyap A, Wingard J, Cagnoni P, Jones R, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-. Biol Blood Marrow Transplant. 2002;8:493–500.CrossRefPubMedGoogle Scholar
  40. 40.
    Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22:2194–200.CrossRefPubMedGoogle Scholar
  41. 41.
    Nakasone H, Onizuka M, Suzuki N, Fujii N, Taniguchi S, Kakihana K, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48:1317–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Nakasone H, Kanda J, Yano S, Atsuta Y, Ago H, Fukuda T, et al. A case–control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation. Transpl Int. 2013;26:631–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Milano F, Chien JW, Riffkin I, Gutman JA, Newell L, Pergam SA, et al. Stable Long-term pulmonary function after myeloablative double cord blood transplant. Biol Blood Marrow Transplant. 2012;18:309–13.CrossRefPubMedGoogle Scholar
  44. 44.
    Piñana JL, Martino R, Barba P, Bellido-Casado J, Valcárcel D, Sureda A, et al. Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. Am J Hematol. 2012;87:9–14.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Department of Hematology and OncologyJA Aichi Konan Kosei HospitalKonanJapan

Personalised recommendations